Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tislelizumab + sitravatinib + docetaxel in previously treated advanced non-small cell lung cancer
ChiCTR2200065547Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, sitravatinib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: 6-month progression-free survival rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
tislelizumabsitravatinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200065547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065547.